Citizen Portal
Sign In

Get Full Government Meeting Transcripts, Videos, & Alerts Forever!

Get email alerts on the Psilocybin Regulation topic

No spam. Unsubscribe anytime.

Senate refines Oregon’s psilocybin rules, adds disclosure and data‑sharing safeguards

3297497 · May 13, 2025
AI-Generated Content: All content on this page was generated by AI to highlight key points from the meeting. For complete details and context, we recommend watching the full video. so we can fix them.

Summary

House Bill 23‑87 updates Measure 109 implementation: it protects licensed providers offering psilocybin services from discipline for acting within their training, enables limited complaint and disciplinary data sharing between agencies, reduces advisory board size, and requires potency labeling and other program clarifications.

The Oregon Senate on May 12 approved House Bill 23‑87, a package of technical and policy updates to the state’s psilocybin services framework established by Measure 109 (2020). The measure passed after floor presentation by Senator Gorsuch.

Gorsuch said HB 23‑87 aims to refine program implementation based on early experience and to balance patient access, provider accountability and public safety. "Under HB 2,387, providers may discuss psilocybin treatment... and for license holders under Oregon's psilocybin program, they may offer those services without fear of professional discipline for acting on their training and licensure," Gorsuch said on the floor.

Key provisions described on the floor include statutory protections for licensed health care providers who are also certified psilocybin service facilitators; narrower, targeted information sharing between the Oregon Health Authority and professional licensing boards about complaints and disciplinary matters (preserving confidentiality where required); and a reduction in the size of the Oregon Psilocybin Advisory Board while retaining representation for service facilitators, tribal voices, harm‑reduction experts and behavioral‑health professionals.

The bill also directs stronger product labeling requirements, including potency disclosure, clarifies data collection and program reporting duties for the Oregon Health Authority, and refines standards for denial, suspension or revocation of licenses.

Senators voted to pass the bill; the Senate record shows the measure received the constitutionally required majority and was declared passed. Sponsors described HB 23‑87 as a refinement that preserves voter intent from Measure 109 while improving safety and regulatory clarity.